Psyence BioMed Doses Multiple Patients in Phase IIb Psilocybin Trial for Adjustment Disorder
Reuters
Nov 06
Psyence BioMed Doses Multiple Patients in Phase IIb Psilocybin Trial for Adjustment Disorder
Psyence Biomedical Ltd. has announced a significant milestone in its ongoing Phase IIb clinical trial evaluating nature-derived psilocybin, in combination with psychotherapy, as a potential treatment for Adjustment Disorder in palliative care. Multiple patients have now been successfully dosed across two active clinical sites-the Empax Center in Perth and the Mind Medicine Australia Clinic in Melbourne. The company has also activated a third site, Paratus Clinical Research in Melbourne, to accelerate enrollment and data collection. The trial is designed to meet rigorous regulatory standards, with a larger sample size, randomized multi-site structure, and aims to generate high-quality data to support future approvals. Topline results from the study are anticipated by the end of 2026. No results have been presented yet.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569434-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.